It should be noted that a large retrospective series revealed that there is no real difference between OvRec based on whether or not the patients had an EGFRmut or EGFR wild-type tumor and that LR rates were similar among tumors with EGFR mutated (16.5%) and EGFR wild-type (16.8%) tumors in a preadjuvant osimertinib, but recent patient cohort.29 The gene discussed is EGFR; the disease is neoplasm.